Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Claims25
A method of extending dextromethorphan plasma levels in a human being that is an extensive metabolizer of dextromethorphan and is in need of treatment with dextromethorphan, comprising co-administering:
- 1) a hydroxybupropion, a threohydroxybupropion, an erythrohydroxybupropion, or a bupropion with 2) a dextromethorphan, to the human being once or twice a day for at least eight consecutive days, wherein the daily dose of the dextromethorphan is about 15 mg to about 300 mg, and co-administering the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion, or the bupropion with the dextromethorphan results in a Cavg of the dextromethorphan that, on the eighth day, is at least about 20 times the Cavg that would be achieved by administering the same amount of the dextromethorphan without the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion, or the bupropion for eight consecutive days.
A method of extending dextromethorphan plasma levels in a human being that is an extensive metabolizer of dextromethorphan and is in need of treatment with dextromethorphan, comprising co-administering:
- 1) a hydroxybupropion, a threohydroxybupropion, an erythrohydroxybupropion, or a bupropion with 2) a dextromethorphan, to the human being once or twice a day for at least eight consecutive days, wherein the daily dose of the dextromethorphan is about 20 mg to about 250 mg, and co-administering the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion, or the bupropion with the dextromethorphan results in a Cavg of the dextromethorphan that, on the eighth day, is at least about 15 times the Cavg that would be achieved by administering the same amount of the dextromethorphan without the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion, or the bupropion for eight consecutive days.
A method of extending dextromethorphan plasma levels in a human being that is an extensive metabolizer of dextromethorphan and is in need of treatment with dextromethorphan, comprising co-administering:
- 1) a hydroxybupropion, a threohydroxybupropion, an erythrohydroxybupropion, or a bupropion with 2) a dextromethorphan, to the human being once or twice a day for at least eight consecutive days, wherein the daily dose of the dextromethorphan is about 50 mg to about 400 mg, and co-administering the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion, or the bupropion with the dextromethorphan results in a Cavg of the dextromethorphan that, on the eighth day, is at least about 15 times the Cavg that would be achieved by administering the same amount of the dextromethorphan without the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion, or the bupropion for eight consecutive days.
Dependencies are inferred from the claim text.